Brief: Entrada Therapeutics Reports Q3 Loss Per Share Of $0.80
07/11/2022 12:52
Nov 7 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
* ENTRADA THERAPEUTICS INC- CASH RUNWAY INTO 2H 2024 WITH
$216
MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS
OF SEPTEMBER 30, 2022
* ENTRADA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.80
Source text for Eikon: ID:nGNX1xVxL6
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview